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Abstract While the central nervous system (CNS) was
once thought to be excluded from surveillance by immune
cells, a concept known as “immune privilege,” it is now
clear that immune responses do occur in the CNS—giving
rise to the field of neuroimmunology. These CNS immune
responses can be driven by endogenous (glial) and/or
exogenous (peripheral leukocyte) sources and can serve
either productive or pathological roles. Recent evidence
from mouse models supports the notion that infiltration of
peripheral monocytes/macrophages limits progression of
Alzheimer's disease pathology and militates against West
Nile virus encephalitis. In addition, infiltrating T lympho-
cytes may help spare neuronal loss in models of amyo-
trophic lateral sclerosis. On the other hand, CNS leukocyte
penetration drives experimental autoimmune encephalomy-
elitis (a mouse model for the human demyelinating disease
multiple sclerosis) and may also be pathological in both
Parkinson's disease and human immunodeficiency virus
encephalitis. A critical understanding of the cellular and
molecular mechanisms responsible for trafficking of im-
mune cells from the periphery into the diseased CNS will
be key to target these cells for therapeutic intervention in
neurodegenerative diseases, thereby allowing neuroregener-
ative processes to ensue.
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Introduction
Certain sites in the body, in particular the central nervous
system (CNS), eyes, gonads, and maternal–fetal interface,
are known to exhibit limited immunological responses. This
phenomenon represents a highly regulated active process
that is referred to as immune privilege (Wenkel et al. 2000).
As the CNS possesses limited regenerative capacity, it is
invariably susceptible to damage mediated by inflamma-
tion. Accordingly, immune privilege serves to prevent this
damage and to maintain neural health (Galea et al. 2007).
While multiple mechanisms contribute to immune privi-
lege, restriction of peripheral leukocyte traffic from the
periphery to the CNS is a critically important one.
Peripheral leukocyte migration and infiltration into the
brain parenchyma is tightly regulated at the level of the
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DOI 10.1007/s11481-009-9166-2blood–brain barrier (BBB) (Engelhardt 2008a). Despite this
physical barrier and the brain's “privileged” immune status,
neuroimmune surveillance by peripheral leukocytes does
occur, both physiologically and in instances of disease. Our
growing appreciation of the brain–immune interface has
given rise to the field of neuroimmunology. In this article,
we review the implications of CNS immune cell trafficking
for the pathoetiology and potential treatment of neurode-
generative diseases.
Both endogenous and exogenous immune responses
impact the healthy and diseased CNS. The endogenous brain
immune response chiefly consists of brain-resident innate
immune cells known as microglia (Streit et al. 2004; Town et
al. 2005a). These myeloid cells are traditionally regarded as
the resident macrophages of the CNS and are derived from
monocyte precursors during embryogenesis (Alliot et al.
1999; Pessac et al. 2001). Microglia form the first line of
defense against invading CNS pathogens and are often the
first responders to CNS injury. Another endogenous CNS
immune responder is the astrocyte, which is a
neuroectoderm-derived cell that has limited innate immune
properties, including secretion of certain acute-phase reac-
tants and pro-inflammatory cytokines. The term “reactive
gliosis” h a sb e e nu s e dt od e s c r i b ei m m u n ea c t i v a t i o no fg l i a l
cells, including microglia and astrocytes, which exist in a
quiescent (resting) state in the healthy CNS. Following
neural insult, these cells become activated and undergo
hypertrophy accompanied by increased expression of cell
surface immune antigens. Concomitantly, both activated
microglia and astrocytes synthesize and release a myriad of
pro-inflammatory cytokines, chemokines, complement pro-
teins, proteinases, and reactive oxygen species. While this
neuroinflammatory response may be beneficial for clearing
infection and initiating tissue repair mechanisms, if left
unresolved, it exposes sensitive neurons to elevated levels of
potentially toxic molecules, leading to bystander injury. In
fact, there is mounting evidence that chronic neuroinflam-
mation plays a critical role in the pathoetiology of various
neurodegenerative diseases including Alzheimer's disease
(AD), multiple sclerosis (MS), and Parkinson's disease (PD;
Town et al. 2005a, b; Akiyama et al. 2000; Kim and Joh
2006; Dheen et al. 2007; Town 2009).
In addition to CNS endogenous immunity, discrete
populations of exogenous, peripherally derived immune
cells can traffic to the CNS, particularly during disease
states. These populations are derived from bone marrow
precursors, whereas endogenous microglia are mostly
replaced by local CNS progenitors (Eglitis and Mezey
1997; Brazelton et al. 2000; Mezey et al. 2000; Priller et al.
2001; Ajami et al. 2007; Mildner et al. 2007). Peripheral
immune cell migration into the CNS resembles typical
leukocyte extravasation into other organs, involving sto-
chastic induction of mechanisms governing chemoattrac-
tion, cellular rolling, adhesion, and diapedesis across the
vascular wall. Yet, infiltration of these cells into the CNS is
more complex, owing to the existence of the BBB. Recent
reports have furthered our understanding of this unique
structure, establishing functionally independent roles as a
cellular vs. metabolic barrier (Bechmann et al. 2007).
Recruitment of peripheral immune cells at the level of the
BBB is now known to occur primarily at post-capillary
venules (Ransohoff et al. 2003). Infiltration at these sites is
believed to involve two distinct events: (1) transmigration
across the vascular wall into the perivascular space and (2)
progression through the glia limitans (a network of
astrocyte foot processes) into the brain parenchyma (Owens
et al. 2008). Suppression of any one of the mechanisms
governing these events may impede brain entry and
consequently subvert immune surveillance.
CNSendogenousandexogenousimmunitydonotfunction
in isolation from one another; rather, there is a dynamic
interplay between these two arms. Following microglial and
astrocytic activation, chemokines and cytokines released
locally diffuse into the bloodstream thereby attracting leuko-
cytes to the site of inflammation and upregulating the
expression of cellular adhesion molecules, which are neces-
sary for attachment and transmigration across post-capillary
venules (Engelhardt 2008b). Once migrated across the
endothelium, leukocytes enter an enlarged perivascular
compartment, known as the Virchow–Robin space. It is in
this region that leukocytes are “re-stimulated,” maximizing
their invasive potential. However, the vast majority of
infiltrating peripheral leukocytes are retained in this com-
partment and do not penetrate the glia limitans, unless they
are recruited to the diseased CNS (Bechmann et al. 2007;
Ransohoff et al. 2003;T r a ne ta l .1998).
Beneficial actions of central nervous system immune cell
infiltrates
Infiltrating monocytes/macrophages as an anti-amyloid
force in Alzheimer's disease
AD is the most common form of dementia, affecting an
estimated 5.2 million Americans in 2008, and prevalence is
projected to increase to more than 13.2 million by 2050
(Hebert et al. 2003; Plassman et al. 2007). This chronic,
progressive neurodegenerative disorder is pathologically
earmarked by: (1) deposition of amyloid-beta (Aβ) peptides
as β-amyloid plaques, (2) neuronal injury, and (3) low-
level, chronic neuroinflammation characterized by activated
glial cells (Fig. 1). As first proposed by Hardy and Allsop
(1991), the “amyloid cascade” hypothesis purports that
mismetabolism and deposition of Aβ peptides as β-
amyloid plaques is the principal etiopathological event in
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ing in neuronal demise. Although neuroinflammation was
initially thought to be epiphenomenon, multiple lines of
evidence now show that it is directly involved in AD
pathoetiology. The most compelling data come from
epidemiologic studies showing that exposure to nonsteroi-
dal anti-inflammatory drugs is inversely associated with
risk for AD (t' Veld et al. 2001; Szekely et al. 2004, 2007).
While microglia are capable of phagocytosing Aβ in vitro,
ultrastructural studies in AD patients suggest that these
cells are not competent to take up and clear β-amyloid in
vivo (Wisniewski et al. 1989, 1991;F r a c k o w i a ke ta l .
1992).
Although AD lacks prominent infiltrates of peripheral
leukocytes present in prototypical autoimmune neurode-
generative diseases such as MS (Town et al. 2005b; Aisen
2000), AD patients suffering rare comorbidity of stroke
have been shown to exhibit brain-infiltrating macrophages.
In early pioneering studies, Wisniewski and colleagues
demonstrated that these macrophages contained β-amyloid
fibrils (Wisniewski et al. 1991; Frackowiak et al. 1992;
Jucker and Heppner 2008), suggesting a productive plaque
clearance response mediated by these infiltrating innate
immune cells. These findings laid the groundwork for
recent studies examining the role of peripheral macro-
phages in β-amyloid clearance from the brain. Specifically,
Jucker and Rivest generated bone marrow chimeras to
follow peripheral immune cells in transgenic AD mouse
models. Following irradiation of the APP23 AD model
mouse line and subsequent transplantation of chimeric bone
marrow into these animals, they demonstrated that a small
percentage (about 1%) of brain-resident microglia were
peripheral recruits, and about 20% of β-amyloid plaques
were associated with blood-borne macrophages (Jucker and
Heppner 2008; Stalder et al. 2005; Simard et al. 2006).
While these intriguing reports begged the question of
whether a relatively small percentage of brain-infiltrating
monocytes/macrophages played a functional role in restrict-
ing cerebral amyloidosis, recent studies by Ajami and
Mildner have suggested that the act of irradiation, by itself,
results in BBB damage and leukocyte recruitment to the
otherwise normal CNS (Ajami et al. 2007; Mildner et al.
2007). Further, those authors concluded that local micro-
glial cells accounted for the majority of the innate immune
response to CNS injury. Thus, (1) the specificity of
monocyte/macrophage infiltration in response to CNS
disease and (2) the origin–peripheral vs. CNS–resident of
these potentially neurodegenerative disease-limiting macro-
phages/microglia is somewhat controversial.
Even so, Mildner and colleagues observed mainly chemo-
kine receptor CCR2
+ monocytes/macrophages populating
CNS sites after irradiation (2007). This observation becomes
important when considering a study from El Khoury and
colleagues, who crossed an AD mouse model with animals
deficient in CCR2, thereby interrupting brain recruitment of
peripheral monocytes. These bigenic mice had markedly
diminished infiltrates of microglia/macrophages near β-
amyloid plaques and demonstrated heavier brain amyloid
burden than parental AD model mice (El Khoury et al.
2007). Butovsky and colleagues (2007) took a different
approach and selectively ablated dendritic-like innate im-
mune cells by systemic injection of diphtheria toxin in mice
genetically engineered to target toxicity to CD11c
+ cells.
They found that ablation of these CD11c
+ cells resulted in
greater cerebral amyloid burden, suggesting a normal
amyloid clearance role for these immune cells. While these
studies suggested that peripheral innate immune cells were
an important anti-amyloid force, direct evidence for this was
lacking.
Two recent reports provide positive evidence that
peripheral monocytes/macropahges can act to restrict β-
amyloid plaques. In the first paper (Town et al. 2008), we
found that transforming growth factor beta (TGF-β)-Smad
2/3 signaling in innate immune cells serves the maladaptive
role of suppressing brain infiltration of peripheral mono-
cytes/macrophages. TGF-β, a pleiotropic polypeptide cyto-
kine, plays a pivotal role in immune suppression and
functions to maintain an “immune privileged” environment
in the CNS. This is particularly apparent in conditions of
neurodegenerative disease such as AD, where TGF-β1
mRNA has been shown to be increased by approximately
3-fold vs. nondemented control brains (Wyss-Coray et al.
1997, 2001). Importantly, genetic blockade of TGF-β-
Smad 2/3 signaling in innate immune cells of AD model
mice mitigates AD-like pathology, including cerebral
amyloidosis and brain inflammation. In this model, TGF-
Fig. 1 Confocal microscopy reveals activated microglia (green
signal) clustered around Aβ deposits (magenta signal) in an 18-
month-old Tg2576 mouse model of AD. Reproduced from Town et al.
(2008)
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macrophages (and not in brain-resident microglia), resulting
in their brain entry (Fig. 2) and clearance of β-amyloid.
Thus, it seems that removing an immunosuppressive TGF-
β signal to peripheral macrophages “sensitizes” these cells
to enter into the brain, where they take up a professional
phagocyte role to clear β-amyloid deposits. Importantly,
this beneficial anti-amyloid effect does not come at the cost
of increased brain inflammation, as these peripheral
macrophage immigrants (1) display a CD45
+CD11b
+Ly-
6C
- cell surface phenotype known to mark “anti-inflamma-
tory” macrophages (Geissmann et al. 2003) and (2) occur in
association with increased anti-inflammatory interleukin
(IL)-10 levels in brains of Tg2576 AD model mice crossed
with mice deficient in TGF-β-Smad 2/3 innate immune
signaling (Town 2009; Town et al. 2008).
In a second recent study, Hawkes and McLaurin (2009)
performed two complementary in vivo experiments
designed to elucidate the putative role of the perivascular
macrophage subset in a pathology known as cerebral
amyloid angiopathy (CAA; defined as presence of β-
amyloid deposits in cerebral vessels), which occurs in
83% of AD cases (Ellis et al. 1996). In one model, they
administered liposome-encapsulated clodronate, an intra-
cellular toxin, to the TgCRND8 mouse model of AD in
order to deplete perivascular macrophages. Using this
approach, they showed that removal of perivascular macro-
phages was associated with significantly (~5-fold) in-
creased CAA pathology in AD model mice. In a second
set of experiments, the authors stimulated perivascular
macrophage turnover by administering chitin to TgCRND8
mice. They noted an approximate 3-fold reduction in
thioflavin-S positive β-amyloid deposits in cerebral vessels
using this experimental approach. Thus, perivascular
macrophages (likely of peripheral origin) represent a unique
macrophage subset capable of restricting vascular β-
amyloid deposits.
Brain recruitment of leukocytes in West Nile virus
encephalitis limits infection
West Nile virus (WNV) is a mosquito-transmitted single-
stranded RNA virus that is the most common cause of
epidemic viral encephalitis in North America and has recently
become a pandemic (Campbell et al. 2002; Debiasi and Tyler
2006; Gould and Fikrig 2004; Gubler 2007). WNV is both
neurotrophic (capable of infecting neurons) and neurovirulent
(damaging to the CNS); yet, most infections in humans are
asymptomatic, while the elderly and immunocompromised
are particularly at risk for life-threatening brain disease,
including meningitis and encephalitis (Campbell et al. 2002;
Davis et al. 2006). In the mouse model of lethal WNV
encephalitis, animals first develop systemic infection, and
WNV then crosses the BBB, culminating in encephalitis and
ultimately death within weeks (Wang et al. 2001, 2004).
During the initial systemic phase of WNV infection, antiviral
immune responses including induction of type I interferons
(Anderson and Rahal 2002; Brinton 2001; Gilfoy and Mason
2007), humoral immunity (Diamond et al. 2003a, b), and
cellular immunity including γδ T cells (Wang et al. 2003a),
CD4
+ T cells (Kulkarni et al. 1991; Sitati and Diamond
2006), and CD8
+ Tcells (Shrestha and Diamond 2004, 2007;
Shrestha et al. 2006;S i t a t ie ta l .2007; Wang et al. 2003b)
serve to limit viral infectivity.
After establishing a replicative pool in the periphery, WNV
migrates into the CNS, usually 4–7d a y sa f t e ri n f e c t i o n( W a n g
et al. 2004; Diamond et al. 2003a, b). Viral CNS penetration
typically coincides with encephalitis, characterized by CNS
e n t r yo fm a c r o p h a g e s ,C D 4
+ Tc e l l s ,C D 8
+ Tc e l l s ,n a t u r a l
killer T cells, and dendritic cells (Glass et al. 2005; Fig. 3a).
However, it was previously unclear whether CNS infiltration
of leukocytes played a deleterious or beneficial role in lethal
WNV encephalitis. Glass and coworkers (2005) found that
CNS expression of the chemokine receptor CCR5 and its
ligand CCL5 were increased following WNV infection of
wild-type mice, and this was associated with infiltration of
peripheral leukocytes including CD4
+ and CD8
+ Tc e l l s ,
natural killer cells, and macrophages bearing the CCR5
receptor. These authors undertook a genetic approach to
infect CCR5-deficient mice vs. wild-type animals with WNV,
and they found that CCR5 deficient animals were more
susceptible to lethal WNV encephalitis, had increased brain
viral burden, and had markedly reduced brain leukocyte
traffic compared to their wild-type counterparts. Interestingly,
these authors were able to reverse this pathogenic CCR5-
deficient phenotype by adoptively transferring CCR5 wild-
Fig. 2 Confocal microscopy showing vascular Aβ deposits (green
signal) and infiltrating blood-borne macrophages (red signal)i na n
18-month-old Tg2576 AD mouse model deficient in TGF-β-Smad 2/3
innate immune signaling. Reproduced from Town et al. (2008)
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2005). In a related report, McCandless and colleagues (2008)
examined brain tissues from mice or humans with WNV
encephalitis for expression of the chemokine CXCL12 and
its receptor, CXCR4. A prior study in mice showed that
expression of CXCL12 at the BBB retained infiltrating
monocytes within the perivascular spaces of the CNS
microvasculature, thereby limiting monocyte entry into the
CNS parenchyma (McCandless et al. 2006). They found a
reduction in CXCL12 expression and an increase in CXCR4
levels in WNV-infected brains. To determine whether
increased CXCR4 levels following WNV encephalitis re-
stricted CNS leukocyte traffic and thereby promoted viral
infectivity, these authors treated mice with a CXCR4
antagonist beginning at the time of WNV infection. They
noted increased survival in treated mice following infection
that was associated with enhanced migration of WNV-
specific CD8
+ T cells into the brain parenchyma, which
likely neutralized the virus (McCandless et al. 2008).
It is interesting that most WNV infection in humans is
asymptomatic (Campbell et al. 2002; Davis et al. 2006),
underscoring that host immune mechanisms must be in
place to suppress WNV infection. We hypothesized that
Toll-like receptor 7 (Tlr7), a phylogenetically conserved,
germline-encoded pattern recognition receptor that plays a
key role in initiating innate immune responses to single-
stranded RNA (Qureshi and Medzhitov 2003; Yamamoto et
al. 2004; Lund et al. 2004), may serve to limit WNV
infectivity. To test this hypothesis, we infected Tlr7-
deficient mice with a dose of WNV at which 50% of
wild-type mice succumb to mortality (LD50)a n df o u n d
that 91% of Tlr7-deficient mice died. Similarly, infection
of MyD88-deficient mice (which lack Tlr7-mediated
innate immune responses) with the same dose of WNV
resulted in 85% mortality. Both Tlr7- and MyD88-
deficient mice had increased viral burden in the blood,
brain, and spleen, and while Tlr7-deficient animals
manifested increased systemic levels of most pro-
inflammatory innate immune cytokines, they had reduced
abundance of IL-12/23 mRNA both systemically and in
the brain. These effects occurred with reduced homing and
infiltration of CD45
+ leukocytes and CD11b
+ monocytes/
macrophages into brains of both Tlr7- (Fig. 3b)a n d
MyD88-deficient mice, despite increased brain viral
burden in these knockouts. These data led us to hypoth-
esize that WNV-induced, Tlr7-dependent IL-12 or IL-23
production in the CNS might serve to recruit peripheral
monocytes/macrophages to neutralize the virus. Several
lines of evidence support this notion: (1) IL-23, but not
IL-12, was able to directly induce macrophage chemotaxis
in an in vitro migration assay, (2) Tlr7-deficient macro-
phages had reduced abundance of the shared IL-12/23
receptor subunit (IL-12Rβ1 )a n df a i l e dt oh o m et oI L - 2 3
in vitro, and (3) mice-deficient in IL-23, but not IL-12,
phenocopied Tlr7 and MyD88 knockouts on reduced
survival and leukocyte infiltration and homing to the
CNS after challenge with lethal WNV encephalitis (Town
et al. 2009; Finberg and Wang 2009;v a nO o i j2009).
Thus, a model emerges where microglia first detect CNS-
invading WNV by using Tlr7 to sense viral single-
stranded RNA. By signaling through MyD88, microglial
cells then secrete high levels of IL-23, which attracts
infiltrating monocytes/macrophages and other leukocytes
to the CNS, where they function to neutralize the virus.
West Nile virus “Aikido”: using host innate immunity
against the host
While the above evidence clearly implicates CNS leukocyte
infiltrates as beneficial in the host's fight against lethal
WNV encephalitis, just as in the Japanese martial art
“Aikido,” the virus has evolved an elegant form of defense
against host innate immunity. We hypothesized that Tlr3, an
innate immune pattern recognition receptor that recognizes
viral double-stranded RNA (Alexopoulou et al. 2001; Town
et al. 2006), may function to militate against WNV
infectivity. As a positive single-stranded RNA virus,
WNV produces double-stranded RNA during its life cycle,
and we predicted that Tlr3-deficient mice would fail to
mount an innate immune response to the virus and thus be
more susceptible to lethal encephalitis. Strikingly, these
knockout mice were resistant (40% survival) to a dose of
WNV at which 0% of wild-type mice survived (LD100).
Interestingly, Tlr3-deficient mice had increased viral load in
the circulation but reduced production of innate immune
cytokines including IL-6 and tumor necrosis factor-alpha
(TNF-α) versus wild-type counterparts. In parallel, Tlr3
knockouts had reduced viral burden and inflammatory
pathology in the brain after WNV infection, and they also
showed markedly reduced neuronal pathology and a
strikingly intact BBB compared with wild-type mice. It is
well known that certain innate immune cytokines, including
IL-6 and TNF-α, are able to “permeabilize” the BBB when
produced systemically at high levels. To test whether IL-6
or TNF-α responses to WNV infection might act in this
way, we infected IL-6- or TNF-α receptor-I-deficient mice
with WNV and monitored animals for mortality and BBB
compromise. While we did not detect a difference
between IL-6-deficient and wild-type control mice, TNF-
α receptor I knockouts demonstrated significantly reduced
mortality after LD100 WNV challenge associated with
reduced leakiness of the BBB (Wang et al. 2004; Diamond
and Klein 2004). Thus, while CNS entry of activated
leukocytes is a critical host defense mechanism against
WNV, the virus has evolved to combat host immunity by
using the host's own systemic pro-inflammatory cytokine
466 J Neuroimmune Pharmacol (2009) 4:462–475response to open the BBB in order to gain access to and
infect neurons.
Neuroprotective role of peripheral T cell infiltrates
in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a rapidly
progressive, ultimately fatal neuromuscular disease
pathologically characterized by degeneration of neurons
in the motor cortex, brain stem, and spinal cord
(Rowland and Shneider 2001). This primarily late-onset
neurodegenerative disease affects an estimated 20,000
Americans, and ~5–10% of these cases are purely
heritable forms of the disease (Wijesekera and Leigh
2009). Although the mechanisms underlying motor
neuron loss are not completely understood, genetic
Fig. 3 a Confocal image of a
wild-type C57BL/6 mouse brain
6 days after WNV infection.
Green signal indicates infiltrat-
ing leukocytes, red signal shows
WNV-infected brain cells, and
blue signal shows DAPI cell
nuclei. b Brain flow cytometry
results 6 days after WNV
infection of wild-type vs.
Tlr7-deficient mice. Note the
reduction in brain-infiltrating
immune cell subsets in
Tlr7-deficient mice. Reproduced
from Town et al. (2009) with
permission from Cell Press
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gliosis, and excitotoxicity as disease-propagating factors
(Pasinelli and Brown 2006) .T h er o l eo ft h ep e r i p h e r a l
immune system—specifically infiltrating T cells—in the
pathoetiologic neuroinflammatory component of ALS has
only recently been examined. Initial reports suggested that
the presence of these autoreactive T cells may be
epiphenomenon or represent a secondary response with
minor deleterious immune effects following neuronal
injury (Holmoy 2008).
However, two recent independent reports suggest the
converse: that a secondary T cell response may actually be
beneficial in the context of ALS. In the first study by Beers
and coworkers, ALS model mice expressing mutant
copper–zinc superoxide dismutase (SOD1), the most
common mutation linked to familial ALS, were crossed
with recombination activating gene-2 deficient mice, which
lack functional T cells and B cells. Similarly, Chiu and
colleagues suppressed T-cell-mediated adaptive immune
responses in ALS model mice by crossing SOD1 mutant
animals with T-cell receptor β-chain deficient mice, which
lack thymocyte development. Interestingly, both bigenic
strains in these studies evidenced reduced microgliosis and
accelerated rates of neurodegeneration (Beers et al. 2008;
Chiu et al. 2008). Thus, these studies suggest that
infiltrating CD4
+ T cells in particular may confer neuro-
protection by shifting the trophic/cytotoxic balance of glia
in favor of the former. Interestingly, it was previously
shown that (presumed infiltrating) DCs and the chemokine
monocyte chemoattractant protein 1 were increased in
spinal cord tissue from ALS patients and in the mutant
SOD1 mouse model of ALS (Henkel et al. 2004, 2006). It
is unclear whether these types of innate immune responses
are protective or deleterious in ALS. Yet, combined
evidence from the above studies can be interpreted as
supporting the notion that promoting productive dialog
between the adaptive and innate arms of the immune
system via engaging infiltrating CD4
+ T cells may militate
against ALS pathology. However, it should be noted that
this is a relatively new area of exploration, and we await
further confirmation of this hypothesis.
Deleterious effects of central nervous system leukocyte
traffic
Auto-aggressive T cells cooperate with antigen-presenting
cells to initiate demyelination in multiple sclerosis
MS is the most common CNS autoimmune disorder, affecting
over 250,000 Americans and over one million individuals
worldwide (Steinman 1996). The clinical symptoms of MS
are attributable to inflammatory lesions in CNS white matter
regions that frequently lead to blindness, loss of motor
control, and sensory dysfunction. The pathology of MS is
due to an attack on the CNS by the immune system, resulting
in demyelination of neuronal axons. Clinical symptoms
manifest due to an inability of nerve cells in the brain and
spinal cord to communicate via action potentials that
propagate down axon fibers. It had long been presumed that
antigens present on myelin-producing cells were protected
from the immune system owing to residing in the “immune
privileged” CNS. However, myelin-reactive T cells that
likely recognize a structurally similar viral antigen (known
as “molecular mimicry”) are present in the peripheral blood
of normal individuals, suggesting that the pathology of the
disease may be due to maladaptive CNS entry of autoim-
mune T cells (Fujinami and Oldstone 1985; Wucherpfennig
and Strominger 1995).
The active lesions of MS are characterized by immune cell
infiltrates composed of macrophages, T cells, and B cells
(Traugott et al. 1982), although it is widely accepted that
CNS invasion of encephalitogenic CD4
+ T cells is the key
pathoetiologic event in MS. Experimental autoimmune
encephalomyeltits (EAE) is the most widely used mouse
model of MS and is established by immunizing animals with
myelin antigen(s) in the presence of adjuvant and pertussis
toxin, resulting in (1) development of autoaggressive T cells,
(2) CNS leukocyte infiltration, and (3) demyelination in the
brain and particularly the spinal cord (Fujinami and Oldstone
1985). Activation of endogenous brain microglia occurs in
both human disease and in the EAE mouse model (Greter et
al. 2005). Once activated, it is believed that resident
microglia chemoattract peripheral pro-inflammatory T helper
type 1 (Th1) cells into the CNS. After infiltrating into the
CNS, these cells interact with activated microglia, which
serve as antigen-presenting cells (APCs; Greter et al. 2005).
The importance of T cell/microglial cell interaction in the
immunopathology of EAE is underscored by a report from
Heppner and colleagues (2005). The authors generated
CD11b-HSVTK transgenic mice, which express herpes
simplex thymidine kinase in macrophages and microglia,
thereby allowing deletion of these cells following ganciclovir
treatment. They definitively showed that abrogation of
microglial activation inhibited development and maintenance
of inflammatory CNS lesions.
Once infiltrated into the CNS of MS patients or EAE
model mice, a key molecular event underlying immunopa-
thology is interaction between the CD40 receptor and its
cognate ligand, CD40 ligand (CD40L). Activated Th1 cells
express CD40L and interact with CD40-bearing reactive
microglia in active MS or EAE lesions (Gerritse et al. 1996;
Grewal et al. 1996; Tan et al. 1999; Howard et al. 1999;
Becher et al. 2001). Early studies indicated that the
interaction between CD40
+ microglia and CD40L
+ T cells
initiated production of interferon (IFN)-γ by reactive T
468 J Neuroimmune Pharmacol (2009) 4:462–475cells, which in turn acted as a stimulus for increased
expression of CD40 on microglia. This feed-forward
mechanism would lead to enhanced production of IFN-γ
by activated T cells and TNF-α by reactive microglia, the
result of which would be chronic activation of APCs via the
CD40 pathway (Tan et al. 1999). This immune interaction
is pathogenic, as treatment with anti-CD40L antibody or
genetic deficiency in CD40L have both been shown to
prevent disease development and reduce disease progres-
sion in EAE mice (Gerritse et al. 1996; Grewal et al. 1996;
Howard et al. 1999). Further, recent preclinical assessment
of therapeutic blocking antibodies against human CD40 in
a nonhuman primate model of MS showed efficacy when
administered early in disease development as well as after
the onset of brain inflammation (‘t Hart et al. 2008). These
encouraging results suggest that blockade of the CD40–
CD40L immune interaction may be a viable therapeutic
approach for MS by opposing pro-inflammatory T-cell
activation.
Transfer of an expanded population of myelin-reactive
encephalitogenic CD4
+ Th1 lymphocytes into naïve recip-
ient mice can also induce EAE. In order to recognize their
target, these T cells depend on interaction with APCs
expressing self myelin antigen in the context of major
histocomptibility complex (MHC) class II. Utilizing a
mouse model in which MHC class II expression was
restricted to dendritic cells (DCs), Greter and coworkers
(2005) demonstrated that DCs are capable of licensing CNS
immune invasion. In this system, a population of DCs
associated with the meninges and CNS blood vessels
permitted encephalitogenic T cells to recognize self-
myelin antigen, leading to CNS invasion and subsequent
immunopathology. These DCs have been reported in
normal human brain and potentially represent an interface
between the CNS and the immune system in the context of
EAE-type brain inflammation (Matyszak and Perry 1996).
Interestingly, TGF-β signaling likely acts as an immuno-
suppressive signal to DCs, thereby mitigating DC-induced
CNS leukocyte infiltration. Specifically, targeted functional
inactivation of the TGF-β receptor in DCs results in a high
frequency of T cells in the CNS along with increased levels
of pro-inflammatory cytokines and acute-phase reactants in
EAE mice (Laouar et al. 2008).
In addition to CNS infiltration of CD4
+ T cell subsets,
CD8
+ T cell infiltrates are present during the terminal stage
of EAE (Laouar et al. 2008). In early work, Sun and
colleagues showed that a CD8
+ T cell subset could suppress
induction of EAE in Lewis rats, suggesting that these cells
were counter-regulatory to encephalitogenic Th1 cells (Sun
et al. 1988). However, mice deficient in CD8 show less
mortality but a higher frequency of relapse than wild-type
animals, suggesting that CD8
+ T lymphocytes may con-
tribute as both effectors and regulators in EAE (Koh et al.
1992). While it is generally accepted that MHC class II-
bearing APCs and Th cells are the main players in the
pathogenesis of MS, new evidence has implicated MHC
class I, namely human leukocyte antigen-A3 (HLA-A3)
and HLA-A3-restricted CD8
+ Tcells in the pathogenesis of
MS (Friese et al. 2008). These results provide a molecular
mechanism for the contribution of CD8
+ T cells to the
pathogenesis of EAE and MS, as interaction between
CD8
+ T cells and APCs bearing MHC class I molecules
reveals a complex network of MHC interactions that may
contribute to onset of EAE and MS. The description of
myelin-derived peptides that are MHC class I restricted
and recognized by CD8
+ T cells represents a new avenue
toward exploration of the role of CD8
+ T cells in
demyelinating diseases.
Interleukin-12 versus Interleukin-23 and Interleukin-17
in the pathogenesis of demyelinating disease
IL-12 plays a dominant role in orchestrating differentiation of
Th1 effectors and mediating Th1-associated autoimmune
diseases (Adorini 1999; Adorini et al. 1997). IL-12 is a
heterodimeric protein (known as p70) secreted predominant-
ly by activated APCs and consists of a pair of disulfide-
linked subunits designated p40 and p35 (Becher et al. 2002).
However, the “common chain” p40 subunit of IL-12 is
shared with another heterodimeric cytokine, IL-23, which is
comprised of p40 and p19 subunits (Oppmann et al. 2000).
This sharing of the p40 subunit between full-length IL-12
and IL-23 heterodimers has made it difficult to determine the
specific contribution of these cytokines to MS and EAE.
However, using gene-targeting approaches, Becher and
colleagues (2002) demonstrated that mice deficient in the
p35 subunit of IL-12 were susceptible while p40 null mice
were resistant to EAE. In a later complementary study, Cua
and coworkers (2003) demonstrated that mice specifically
lacking IL-23, and not IL-12, were resistant to EAE. These
authors found that the interaction between IL-23-producing
CNS DCs and T cells regulates encephalitogenicity during
the effector phase of EAE (Cua et al. 2003). When taken
together, these studies strongly implicate IL-23—and not IL-
12—in EAE immunopathogenesis.
There is also mounting evidence supporting the role of
IL-23 in the immunopathogenesis of MS. For example, IL-
23 expression is elevated in DCs from MS patients
compared to healthy donors (Vaknin-Dembinsky et al.
2006). Furthermore, IL-23 promotes expression of the
cytokine IL-17, resulting in differentiation of CD4
+ T
helper 17 (Th17) effector cells from naïve T cells (Luger et
al. 2008). Th17 lymphocytes are capable of transmigrating
across BBB endothelial cells expressing IL-17 and are now
regarded as a pathogenic T cell in MS due to their ability to
functionally interact with and recruit multiple pathogenic
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+
lymphocytes (Ifergan et al. 2008; Kebir et al. 2007). Yet, it
is now generally thought that Th1 and Th17 lymphocyte
subsets are independently capable of inducing CNS
autoimmune disease (Steinman 2008). However, there
likely exists a complicated paradigm where APCs produc-
ing IL-23 and other T-cell polarizing cytokines promote
Th1 and Th17 effector responses, resulting in CNS
trafficking of multiple autoaggressive leukocyte subsets.
Role of peripheral immune cell infiltrates in Parkinson's
disease
PD is the most common movement disorder, affecting over
one million Americans and over four million individuals
worldwide (Dorsey et al. 2007). After AD, it is the next
most common progressive neurodegenerative disorder
affecting elderly individuals over 65 years of age (Dorsey
et al. 2007). Pathologically, PD is characterized by: (1)
preferential loss of dopaminergic neurons, (2) the presence
of Lewy bodies (cytoplasmic inclusions composed princi-
pally of abnormal α-synuclein), and (3) reactive gliosis.
These three pathological hallmarks all occur within a small
region of the midbrain known as the substantia nigra pars
compacta (SNpc). While genetic and pharmacologic models
of the disease have established oxidative stress, mitochon-
drial, and proteosomal dysfunction as disease-perpetrating
events, the mechanism mediating dopaminergic deficit in
sporadic PD remains unknown (Dauer and Przedborski
2003). The search for a PD pathoetiologic mechanism has
uncovered the immune system—particularly innate neuro-
inflammatory responses—as a potential candidate
(Czlonkowska et al. 2002; Whitton 2007). In addition,
recent reports have also implicated the adaptive immune
system in PD pathogenesis.
Although PD is not generally considered an autoimmune
disease, a recent study by Benner and colleagues (2008)
demonstrated that modified “self” epitopes such as nitrated
α-synuclein (N-α-Syn) can overcome immunological tol-
erance and activate peripheral leukocytes in cervical lymph
nodes following administration of the neurotoxin 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to wild-type
mice. In addition, adoptive transfer of T cells from
syngeneic donors immunized with N-α-Syn exacerbated
dopaminergic neuronal loss following exposure to MPTP.
Importantly, these purified CD3
+ populations of T cells
were capable of trafficking to and infiltrating the SNpc
(Benner et al. 2008). In accordance with these findings and
those of the seminal work of McGeer and coworkers
(1988), Brochard and colleagues (2009) reported that T
cells are largely recruited to the SNpc in the brains of
patients with PD. These brain-invading lymphocytes con-
sisted of a heterogeneous population of both CD8
+ and
CD4
+ cells. A similar profile of peripheral leukocyte
infiltration was also present in MPTP mouse models of
PD, further validating the relevance of the model to the
human syndrome (Brochard et al. 2009). Interestingly, both
this experimental model and the clinical syndrome exhibit
BBB dysfunction (Kortekaas et al. 2005). However, it
should be noted that while the BBB appears to be “leaky”
following exposure to MPTP, it is unlikely that this
phenomenon is sufficient to grant peripheral leukocytes
direct access to the diseased brain. Rather, a dysfunctional
BBB is likely one of many steps involved in recruitment of
peripheral immune cells to the PD brain.
To ascertain which T cell subsets might contribute to PD
pathogenesis, Brochard and colleagues (2009) went on to
examine dopaminergic neuronal loss in mice deficient in
one or both subsets of T cells following MPTP intoxication.
Interestingly, mice lacking complete cell-mediated immu-
nity or CD4
+, but not CD8
+, T cells were protected against
MPTP-induced injury, suggesting a pathogenic role of
CD4
+ T cells in the MPTP mouse model of PD. Upon
further elucidation of this pathogenic role, CD4
+ T cells
were found to arbitrate dopaminergic neuronal loss via a
Fas/FasL-dependent mechanism (Brochard et al. 2009). In
addition, a recent report by Reynolds and colleagues further
substantiated the detrimental activities of CD4
+/CD25
−
cells by demonstrating the ability of these effector T cells
to exacerbate microgliosis following exposure to N-α-Syn.
This study also examined the potentially beneficial activ-
ities of infiltrating CD4
+/CD25
+ regulatory T cells (Tregs).
These CNS infiltrating Tregs were capable of suppressing
microgliosis by secreting cytokines that mitigate inflamma-
tory responses or by directly inducing microglial apoptosis
via a similar Fas/FasL-dependent mechanism as described
above (Reynolds et al. 2009). While studies investigating
the role of Tregs in PD have not definitively established
protective vs. deleterious activities at various stages during
disease, it is likely that the Treg lymphocyte subset has the
potential to be mobilized to abrogate PD pathology
(Reynolds et al. 2007, 2009). Taken together, these results
suggest the existence of highly regulated, adaptive immu-
nopathogenic mechanisms at work in PD that may
ultimately be harnessed as therapeutic(s).
Detrimental role of peripheral immune cell infiltrates
in HIV-associated neurocognitive dysfunction
Neurological disease arising from human immunodeficiency
virus (HIV) remains a frequent complication of this viral
infection. Specifically, HIV-associated neurocognitive dys-
function (HAND), which in itself is comprised of a spectrum
ofneurologicalimpairments,continuestoplaguepatientswith
advanced HIV infection despite the advent of highly active
antiretroviral therapy (Ghafouri et al. 2006; Reger et al.
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for HAND are unclear, an abundance of clinical and
laboratory investigations suggest that HIV encephalitis
(HIVE), advancing age, and even comorbid neurodegenera-
tive disease may interact in an additive or synergistic manner
resulting in the clinical phenotype of this disorder (Ghafouri
et al. 2006; Gonzalez-Scarano and Martin-Garcia 2005). It is
well known that peripheral HIV-infected monocytes/macro-
phages infiltrate the CNS, resulting in reactive gliosis,
formation of multinucleated giant cells, and neuronal loss
characteristic of HIVE (Ghafouri et al. 2006;G o n z a l e z -
Scarano and Martin-Garcia 2005;B u d k a1991). However,
the role of invading T-cell populations in HIVE-mediated
neurodegeneration has only recently been investigated.
Two studies by Petito and coworkers examined infiltrat-
ing T lymphocytes in the brains of end-stage-acquired
immunodeficiency syndrome (AIDS) patients with and
without HIVE. In their earlier work, they found that
hippocampal effector/memory CD45RO
+ T lymphocytes
were significantly increased in individuals with HIVE.
Interestingly, these CD4
+ and CD8
+ T cells were observed
in direct contact with neurons, underscoring the potential
for lymphocyte-mediated neuronal injury or possibly trans-
receptor-mediated neuronal infection (Petito et al. 2003). In
their follow-up report, these authors observed cytotoxic
CD8
+ T cells in the parenchyma of AIDS patients with
HIVE. The perineuronal localization of these T cells and
their associated cytotoxic granules again suggested T
lymphocyte-mediated neuronal killing (Petito et al. 2006).
As indirect evidence of this pathogenic mechanism, Liu and
colleagues demonstrated that adoptive transfer of Tregs
attenuated reactive gliosis, viral replication, and neuronal
loss in an HIVE mouse model. Importantly, adoptive
transfer of effector T cells in this model had contrary
effects (Liu et al. 2009). Although it is generally accepted
that Tregs suppress antiviral immune responses in the
periphery, it is likely that these same responses may directly
or indirectly target neurons and even exacerbate HIV
dissemination in the CNS. Therefore, specifically gating
the subsets of T lymphocytes that are granted access to the
HIV-infected brain may help resolve infection and conse-
quently prevent or treat HAND.
Concluding remarks
In this review, we have explored both beneficial and
deleterious impacts of peripheral immune cell traffic into
the CNS depending on disease state. The AD brain
responds to pathology by increasing “immune privilege”
barriers that restrict CNS leukocyte traffic, including
upregulation of TGF-β1 expression. While TGF-β1i s
directly neurotrophic (Tesseur et al. 2006), this response
may ultimately be maladaptive as it precludes brain entry of
peripheral monocytes/macrophages. Overcoming this barri-
er by blocking innate immune TGF-β-Smad 2/3 signaling
results in robust brain entry of peripheral macrophages and
restriction of cerebral amyloidosis. In WNV encephalitis,
Fig. 4 Model for detrimental
versus beneficial roles of CNS
immune cell traffic. See text
for references
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+ and
CD8
+ T cells and monocytes/macrophages, into the CNS
also serves a beneficial role to seek out and neutralize the
virus, thereby limiting CNS infectivity. However, the host's
frontline innate immune defense is also capitalized upon by
the virus to permeabilize the BBB, allowing viral entry into
the CNS. Thus, aggressive pro-inflammatory innate im-
mune responses must be kept in check to limit WNV
infection of the CNS and to minimize neuronal bystander
injury. In models of ALS, CD4
+ T lymphocytes infiltrate
the CNS where they may fine-tune glial responses to
promote a neuroprotective microenvironment. In the con-
text of MS and the EAE mouse model, infiltration of
autoaggressive leukocytes including Th1 and Th17 CD4
+ T
cell subsets promotes brain inflammation and associated
CNS injury. Thus, the pathology of MS and EAE under-
scores the importance of restricting “runaway autoimmuni-
ty” leading to CNS lesions. The role of peripheral leukocyte
traffic to the brain is just beginning to be explored in PD,
which was classically thought to be a neurodegenerative
disease without an immune component. However, CD4
+
and CD8
+ T cells are detected in PD patient brains, and
deletion of CD4
+ T cells rescues mice from PD-like effects
of MPTP intoxication. Finally, the impact of cytotoxic T-
cell infiltration in HAND is viewed with increasing interest,
as CD8
+ T cells and their cytotoxic granules are present in
the brains of late-stage AIDS patients with HIVE, suggest-
ing T lymphocyte-mediated neuronal loss.
What emerges from studies reviewed in this article is
that peripheral immune responses in the CNS are neither
inherently beneficial nor damaging. However, controversy
still surrounds whether peripheral immune responses
directed toward self-antigen in the CNS are beneficial, a
concept known as “autoimmune neuroprotection” or “pro-
tective autoimmunity” (Schwartz and Kipnis 2005). A
number of recent reports touch on this debate, suggesting
that early autoaggressive immune responses may accelerate
the pathogenesis of various neurodegenerative diseases (Liu
et al. 2009; Reynolds et al. 2009; Planas and Chamorro
2009). These and other studies also find that curbing this
response via Treg-mediated immunosuppression affords
protection against neurodegeneration, as appears to be the
case with EAE, PD and HIVE (Liu et al. 2009; Reynolds et
al. 2007; Kohm et al. 2002). Conversely, an alternative
view suggests that dysregulation of autoaggressive immune
responses may allow neurodegenerative mechanisms to
persist. This is apparent in studies examining the adverse
activities of Tregs in models of viral encephalitis and ALS
(Bai et al. 2009; Goldstein et al. 2009). Failure to engage
the appropriate immune responses may prevent resolution
of neuroinsults, resulting in a common feature of these
neurodegenerative diseases: chronicity. In the final analysis,
CNS leukocyte traffic may serve either beneficial or
deleterious roles, depending on the brain disease state
(Fig. 4). A critical understanding of the cellular and
molecular mechanisms responsible for this intriguing and
important interface between the CNS and the immune
system will likely lead to novel therapeutics in the future.
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